Anita Suresh
Deputy Director, Head of Genomics Programme,
FIND
Anita Suresh is Deputy Director at FIND, the global alliance for diagnostics, where she heads the Genomics & Sequencing Unit. Anita leads a 12-member multidisciplinary team focused on enabling next-generation sequencing for drug-resistant TB diagnosis, genomic technology evaluation and capacity building for genomic surveillance across COVID-19, antimicrobial resistance and pandemic preparedness. She has 18 years of experience across the biomedical value chain, including upstream and downstream commercialization of in vitro diagnostics, clinical and scientific project management, grant development, technology assessment, R&D and public policy. Anita has an MBA from the Kellogg School of Management, Northwestern University, MSc in Bioinformatics and BSc (Hons) in Molecular Biology, both from the National University of Singapore.

Linfa Wang
Professor, Executive Director,
Duke-NUS
Linfa Wang is a professor of the Programme in Emerging Infectious Diseases at Duke-NUS Medical School, and the inaugural executive director of PREPARE, Ministry of Health, Singapore. He is an international leader in the field of emerging zoonotic viruses and virus-host interaction. His current research focuses on why bats are such an important reservoir for emerging viruses and on how we can learn from bats to make us more resilience to infection and diseases in general. He is a member of the WHO SARS Scientific Research Advisory Committee and played a key role in identification of bats as the natural host of SARS-like viruses. In response to the COVID-19 pandemic, he has served/is serving on multiple WHO committees for COVID-19, including the WHO IHR Emergency Committee. Prof Wang has more than 500 scientific publications, including papers in Science, Nature, NEJM and Lancet. He is currently the Editor-in-Chief for the Virology Journal. Prof Wang was elected to the Australian Academy of Technological Sciences and Engineering in 2010 and the American Academy of Microbiology in 2021. He received the Singapore President Science Award in 2021.

Sarah Mwangi
Implementation Science Expert for Pathogen Genomics,
Africa Centres For Disease Control and Prevention
Dr Sarah Mwangi is the implementation science expert for pathogen genomics at the Africa CDC. Dr Mwangi holds a PhD in Bioinformatics from the South African National Bioinformatics Institute at the University of the Western Cape, a bachelor’s degree in Biochemistry from the University of Nairobi and a higher Diploma in Management of Information Systems from Strathmore University. Dr Mwangi’s genomics and bioinformatics experience spans more than 14 years with consortia in Africa and around the globe, she was a postdoctoral researcher at the Karolinska Institute in Stockholm, Sweden and was a consulting intern with the biomedical informatics team at Illumina Inc. in San Francisco USA. Prior to joining the Africa CDC, Dr Mwangi was a research fellow at the University of Pretoria and the University of Witwatersrand in South Africa. A technology enthusiast with a passion for the use of science and technology innovation for a better world, Dr Mwangi is the recipient of several awards among which include the functional genomics fellowship from the World Health Organisation, the US department of State Techwomen fellowship for emerging leaders and the Spanish senior research fellowship for women in science and technology innovation in Africa.

Phil Febbo
Chief Medical Officer,
Illumina
Phil Febbo, MD was appointed as Chief Medical Officer in March 2018. In this role, he is responsible for developing and executing the Company’s medical strategy to drive genomic testing into healthcare practice. Dr. Febbo has a successful track record of translational research, clinical excellence, and for embedding molecular insights into clinical care. Immediately before joining Illumina, Dr. Febbo served as CMO of Genomic Health. Prior to his five years at Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. Before joining the faculty of UCSF as an associate professor in 2010, Dr. Febbo worked at Duke University Medical Center’s Institute of Genome Sciences and Policy. He completed his internal medicine residency at the Brigham and Women’s Hospital, and his fellowship in oncology at the Dana-Farber Cancer Institute. After which he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). Throughout his career, Dr. Febbo has served as a primary investigator for the Translational Research Program of The Alliance, an NCI-supported cooperative group, where his work focused on incorporating biomarkers into large clinical trials.